Clinical Trial Detail

NCT ID NCT02255097
Title Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

head and neck squamous cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.